AG真人官方

Theralase(R) Releases 2Q2025 Financial Statements

Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 2Q2025 financial statements ("Financial Statements").

Theralase® will be hosting a conference call on Wednesday, September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending June 30^th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to [email protected].

An archived version will be available on the website following the conference call.

Financial Summary:
For the six-month period ended June 30^th:

To view an enhanced version of this graphic, please visit:

¹ Other represents foreign exchange, interest accretion on lease liabilities and / or interest income

Financial Highlights

For the six-month period ended June 30, 2025 versus June 30, 2024:

• Total revenue increased 12% to $310,933 from $276,401
• Cost of sales decreased 4% to $178,966 (58% of revenue) from $186,324 (67% of revenue)
• Gross margin increased 47% to $131,967 (42% of revenue) from $90,077 (33% of revenue)
• Selling expenses decreased 5% to $139,011 from $145,915
• Administrative expenses increased 10% to $995,333 from $907,378, driven primarily by increases in general and administrative expenses, administrative salaries and stock-based compensation
• Research and development expenses increased 1% to $1,460,447 from $1,450,086, reflecting increased activity to support Study II progress
• Net loss for the period increased 1% to $2,423,235 from $2,400,461. This included $471,174 in non-cash charges such as amortization and stock-based compensation.

Operational Highlights

Private Placements:

• On April 14, 2025, the Company completed a non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years.
• On June 17, 2025, the Company completed a non-brokered private placement, issuing 2,855,000 units at $0.20 per unit for gross proceeds of $571,000. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.30 for five years.
• On July 28, 2025, the Company completed a non-brokered private placement, issuing 3,363,134 units at $0.20 per unit for gross proceeds of $672,627. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.30 for five years.

Warrant Extension:

On June 26, 2025, the Company extended the expiry date of 4,800,000 warrants, all of which are exercisable at $0.35 per share. The warrants were issued on June 30, 2023, pursuant to a private placement involving the issuance of 4,800,000 units of the Company. The new expiry date of the warrants is June 30, 2028.

The Company continues to explore additional equity and non-dilutive funding opportunities to support its clinical and commercial milestones.

Study II Update:

As of August 26, 2025:

• 86 patients have been treated with the primary Study Procedure, representing approximately 96% of the total targeted enrollment of 90 patients.
• 70 patients have completed the clinical study being assessed at all assessment visits or have been prematurely removed from the clinical study by the principal investigator for lack of response
• 16 additional patients are pending study completion.

Interim clinical results indicate:

• 61.4% (43/70) patients achieved a Complete Response ("CR") at any point in time
• 70% (49/70) achieved a Total Response (CR + Indeterminate Response ("IR")) (IR = negative cystoscopy with positive urine cytology, without a confirmatory bladder biopsy)
• At the 450-day assessment, 39.5% (17/43) of patients maintained a CR, indicating strong durability of treatment effect.

Theralase® remains on track to complete enrollment in 3Q2025, with data lock targeted for 4Q2026 and regulatory submissions expected in 4Q2026.

For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at .

About Ruvidar®:
Ruvidar® (TLD-1433) is a small molecule, able to be activated by light, radiation, sound and other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses.

About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of cancer, bacteria and viruses, with minimal impact on surrounding healthy tissue.

Additional information is available at and .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.

For investor information on the Company, please feel to reach out .

To view the source version of this press release, please visit